Cell Therapeutics' Pacritinib Phase III Program Takes Off
By Catherine Shaffer
Wednesday, January 9, 2013
Cell Therapeutics Inc., of Seattle, began a much-anticipated Phase III trial for its JAK2 inhibitor, pacritinib, in myelofibrosis. It licensed the drug from Singapore-based S*Bio Pte Ltd. in April for $30 million up front and up to $132.5 million in regulatory and sales milestones.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.